bluebird bio Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : bluebird bio Inc.

BLUE 4.970

0.0%

Jun 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (72)	5/23/2014 10:29:57 AM
From: idos	Read Replies (1) of 163

Just note that the clinical trial you linked to is the USA one (HGB-204) and the Cavazzana abs is from the French (HGB-205) study. investor.bluebirdbio.com There are some preclinical data on the improved vector such as here: abstracts2view.com Nothing worrying. On VCN: it is believed that between 0.3 - 3 at release should be ok (not too high to minimize the risks of insertional oncogenesis) and it may decrease in time.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next